- Q3 2023 Jubilant Pharmova Ltd Earnings Call TranscriptFeb 03, 2023₹343.85 (-1.24%)Earnings
- Q2 2023 Jubilant Pharmova Ltd Earnings Call TranscriptOct 21, 2022₹340.6 (+5.29%)Earnings
- Q1 2023 Jubilant Pharmova Ltd Earnings Call TranscriptAug 02, 2022₹361.05 (-2.81%)Earnings
- Q4 2022 Jubilant Pharmova Ltd Earnings Call TranscriptMay 27, 2022₹404.3 (+1.81%)Earnings
- Q3 2022 Jubilant Pharmova Ltd Earnings Call TranscriptFeb 04, 2022₹526.4 (+0.40%)Earnings
- Q2 2022 Jubilant Pharmova Ltd Earnings Call TranscriptOct 22, 2021₹604.1 (-1.25%)Earnings
- Q1 2022 Jubilant Pharmova Ltd Earnings Call TranscriptJul 23, 2021₹696.9 (-2.59%)Earnings
- Jubilant Pharmova Ltd Investor & Analyst Meet TranscriptJun 18, 2021
- Q3 2021 Jubilant Life Sciences Ltd Earnings Call TranscriptFeb 05, 2021₹935.15 (+2.88%)Earnings
- Q2 2021 Jubilant Life Sciences Ltd Earnings Call TranscriptNov 04, 2020₹528.79 (+1.50%)Earnings
- Q1 2021 Jubilant Life Sciences Ltd Earnings Call TranscriptSep 04, 2020₹620.74 (+1.33%)Earnings
- Q4 2020 Jubilant Life Sciences Ltd Earnings Call TranscriptMay 29, 2020₹330.91 (+1.73%)Earnings
- Jubilant Life Sciences Limited - Special Call TranscriptApr 01, 2020
- Q3 2020 Jubilant Life Sciences Ltd Earnings Call TranscriptJan 31, 2020₹435.44 (-3.55%)Earnings
- Q2 2020 Jubilant Life Sciences Ltd Earnings Call TranscriptOct 25, 2019₹420.03 (-1.45%)Earnings
- Q1 2020 Jubilant Life Sciences Ltd Earnings Call TranscriptJul 26, 2019₹333.61 (-0.22%)Earnings
- Q4 2019 Jubilant Life Sciences Ltd Earnings Call TranscriptMay 17, 2019₹445.99 (-4.09%)Earnings
Jubilant Life Sciences Limited - Special Call Transcript
Good day, ladies and gentlemen, and welcome to the Jubilant Life Sciences Limited conference call to update on company's position with respect to COVID-19 pandemic. (Operator Instructions)
Please note that this conference is being recorded.
I now hand the conference over to Mr. Vineet Mayer, Senior Manager, Investor Relations from Jubilant Life Sciences Limited. Thank you, and over to you, sir.
Thank you. Good evening, everybody. I'm Vineet Mayer from Investor Relations at Jubilant Life Sciences. I thank you for joining this call.
The purpose of this call is to provide an update about the company's position with respect to COVID-19 pandemic. We would discuss our fourth quarter FY '20 and full year '19/'20 financial/operational performance and business outlook in our fourth quarter earnings call and disclosures after our Board meeting in May end. We would appreciate your questions at the end of the call, are restricted only to the company's position with respect to COVID-19
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)